MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
November 30, 2020 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
Provectus Receives Notice of Allowance for Fourth Cancer Combination Therapy Patent from the United States Patent and Trademark Office
July 15, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
- Further patent protection of combinations of intratumoral PV-10 and checkpoint inhibitor (CI) drugs for the treatment of multiple, different, solid tumor cancers KNOXVILLE, TN, July 15, 2019 ...
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
November 12, 2018 09:00 ET
|
Biodesix, Inc.
Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018 BOULDER, Colo. and WASHINGTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Researchers with...
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
October 22, 2018 03:00 ET
|
Biodesix, Inc.
Serum Proteomic Test Could Optimize Treatment by Identifying Patients Unlikely to Benefit from Immunotherapy BOULDER, Colo. and MUNICH, Germany, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Biodesix®...